Study guide
5.3 Differentials in Reproductive and Women's Health
AANP Family Nurse Practitioner Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical History & Lifespan Assessment
Section 1.1: Lifespan Health History: Newborn through Geriatric Care Section 1.2: Social Drivers of Health & Cultural Competence Section 1.3: Risk Assessment and Stratification
2 Chapter 2: Physical Examination & Physical Assessment
Section 2.1: Developmental Milestones & Pediatric Exams Section 2.2: Advanced Adult & Geriatric Physical Exams Section 2.3: Identifying Clinical Red Flags & Abuse/Neglect
3 Chapter 3: Diagnostic Screening, Testing, & Interpretation
Section 3.1: Primary Care Screening Guidelines Section 3.2: Interpreting Diagnostic Laboratory Panels Section 3.3: Ordering & Interpreting Imaging Studies Section 3.4: Electrocardiology & Pulmonary Function Tests
4 Chapter 4: Differential Diagnosis of Cardio-Respiratory & Endocrine Disorders
Section 4.1: Differentials in Cardiovascular Conditions Section 4.2: Differentials in Respiratory Conditions Section 4.3: Differentials in Endocrine and Metabolic Disorders
5 Chapter 5: Differential Diagnosis of GI, GU, & Reproductive Disorders
5.1 Differentials in Gastrointestinal Conditions 5.2 Differentials in Genitourinary and Renal Conditions 5.3 Differentials in Reproductive and Women's Health
6 Chapter 6: Differential Diagnosis of Neuro, MSK, Derm, & Psych Disorders
Section 6.1: Differentials in Musculoskeletal and Neurological Disorders Section 6.2: Differentials in Dermatological and Psychiatric Conditions
7 Chapter 7: Pharmacotherapeutic Principles & Prescribing Guidelines
Advanced Pharmacotherapeutic Principles Safe Prescribing in Special Populations Prescription Writing, Regulation, and Controlled Substances
8 Chapter 8: Evidence-Based Management of Common Primary Care Disorders
Section 8.1: Pharmacological Treatment Plans Section 8.2: Non-Pharmacological & Integrative Management Section 8.3: Referrals, Consultations, and Interprofessional Collaboration
9 Chapter 9: Health Promotion, Education, & Care Coordination
Section 9.1: Patient and Caregiver Education Section 9.2: Ethics, Consent, & Legal Scope in Treatment Planning
10 Chapter 10: Clinical Outcome Evaluation & Treatment Modification
Section 10.1: Monitoring Treatment Efficacy & Patient Adherence Section 10.2: Lab & Diagnostic Follow-Up in Care Monitoring Section 10.3: Identifying Adverse Drug Reactions & Complications Section 10.4: Criteria for Care Plan Modification & Escalation
5.3 Differentials in Reproductive and Women's Health
Key Takeaways Explain This Topic AI
Bacterial Vaginosis is diagnosed via Amsel criteria (clue cells, pH >4.5, positive whiff test) and treated with metronidazole, requiring alcohol avoidance.
Cervical cancer screening is cytology-only every 3 years for ages 21-29, and co-testing or primary HPV every 5 years for ages 30-65.
Abnormal cytology management in women aged 21-24 with ASC-US or LSIL is conservative, requiring repeat cytology in 12 months rather than colposcopy.
CDC STI guidelines recommend Doxycycline 100 mg BID for 7 days as first-line for chlamydia, and Ceftriaxone 500 mg IM for gonorrhea.
Syphilis is screened with nontreponemal tests (RPR/VDRL) and confirmed with treponemal tests (FTA-ABS), treated with Penicillin G benzathine.
Last updated: July 2026
Differentials in Reproductive and Women's Health
Diagnosing reproductive and women's health conditions in primary care requires the Family Nurse Practitioner (FNP) to apply evidence-based guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP), the Centers for Disease Control and Prevention (CDC) Sexually Transmitted Infections Treatment Guidelines, and the United States Preventive Services Task Force (USPSTF). Systematic clinical assessment of vaginitis, abnormal cervical cytology, and sexually transmitted infections is a cornerstone of safe, advanced clinical practice.
Vaginitis
Vaginitis is characterized by vaginal discharge, vulvovaginal irritation, pruritus, or odor. The three most common causes are Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis.
Bacterial Vaginosis (BV): A polymicrobial syndrome resulting from the loss of hydrogen peroxide-producing Lactobacillus species and overgrowth of anaerobes (mainly Gardnerella vaginalis ). It presents with a thin, homogeneous, off-white/gray vaginal discharge with a characteristic "fishy" odor, without vulvovaginal inflammation. Diagnosis is based on the Amsel Criteria (requires 3 of 4):
Homogeneous, thin, white-to-gray discharge.
Vaginal pH >4.5.
Positive Whiff test (release of fishy amine odor upon addition of 10% KOH to vaginal secretions).
Clue cells (vaginal epithelial cells covered in coccobacilli, obscuring cell borders) representing >=20% of epithelial cells on a saline wet mount.
Treatment: Metronidazole 500 mg orally twice daily for 7 days, or Metronidazole 0.75% gel intravaginally daily for 5 days. Alcohol must be avoided during therapy and for 72 hours afterward to prevent a disulfiram-like reaction. Routine treatment of male partners is not recommended.
Vulvovaginal Candidiasis (VVC): Usually caused by Candida albicans . Classic symptoms include intense vulvar pruritus, burning, dysuria, dyspareunia, and vulvar erythema/edema. The discharge is typically thick, white, and curd-like ("cottage cheese" consistency). The vaginal pH is normal (<4.5). Wet mount using 10% KOH reveals pseudophyphae and budding yeast spores.
Treatment: Fluconazole 150 mg orally in a single dose (contraindicated in pregnancy, where topical azoles for 7 days are first-line). Partner treatment is not required.
Trichomoniasis: Caused by the flagellated protozoan Trichomonas vaginalis . Symptoms include a diffuse, malodorous, frothy yellow-green vaginal discharge, vulvar irritation, dysuria, and a "strawberry cervix" (petechiae on the cervix, highly specific but seen in <5% of cases). Vaginal pH is >4.5. Saline wet mount shows motile, flagellated trichomonads swimming. NAAT is the gold standard diagnostic.
Treatment: Metronidazole 500 mg orally twice daily for 7 days (or 2 g orally in a single dose). Simultaneously treating all sexual partners is mandatory, and patients must abstain from intercourse until both partners are treated and asymptomatic.
- Characteristic Bacterial Vaginosis (BV) Vulvovaginal Candidiasis Trichomoniasis
- Primary Etiology Gardnerella vaginalis & anaerobes Candida albicans (fungal) Trichomonas vaginalis (protozoan)
Clinical Discharge Thin, homogeneous, gray-white, malodorous Thick, white, clumpy ("cottage cheese") Frothy, yellow-green, malodorous
Vaginal pH > 4.5 < 4.5 (normal range) > 4.5
Microscopy Findings Clue cells (obscured cell borders) Pseudophyphae & budding yeast Motile, flagellated trichomonads
Whiff Test (KOH) Positive (fishy amine odor) Negative Often positive or variable
Common Symptoms Vaginal odor, increased discharge Intense pruritus, burning, erythema Pruritus, dysuria, strawberry cervix (rare)
First-Line Treatment Metronidazole 500 mg BID x 7 days Fluconazole 150 mg PO single dose Metronidazole 500 mg BID x 7 days
Partner Management Routine treatment not recommended Routine treatment not recommended Yes, partner treatment is required
Cervical Cancer Screening & Pap Smear Abnormalities
Cervical cancer screening guidelines (USPSTF/ASCCP) emphasize age-appropriate screening to prevent over-treatment of transient HPV infections in young women.
Screening Schedule:
Age <21: No screening, regardless of sexual history.
Age 21–29: Cytology (Pap smear) alone every 3 years. Reflex HPV testing is performed only for ASC-US. Primary HPV testing or co-testing is not recommended.
Age 30–65: Cytology alone every 3 years, OR co-testing (cytology + high-risk HPV) every 5 years, OR primary HPV testing every 5 years.
Age >65: Discontinue screening if the patient has had adequate prior negative screenings (3 consecutive negative cytologies or 2 consecutive negative co-tests within the last 10 years, with the most recent test within 5 years) and is not at high risk.
Management of Abnormal Cytology (ASCCP):
ASC-US (Atypical Squamous Cells of Undetermined Significance):
Age >=25: Perform reflex HPV testing. If HPV positive, refer for Colposcopy. If HPV negative, repeat co-testing in 3 years.
Age 21–24: Repeat cytology alone in 12 months. Do not perform reflex HPV testing. If the repeat cytology is ASC-US or worse, repeat again at 12 months. Only refer for colposcopy if the cytology remains abnormal after 24 months of observation.
LSIL (Low-Grade Squamous Intraepithelial Lesion):
Age >=25: If HPV positive, refer for Colposcopy. If HPV negative, repeat cytology/HPV in 1 year.
Age 21–24: Repeat cytology in 12 months. Do not refer for colposcopy immediately.
HSIL (High-Grade Squamous Intraepithelial Lesion):
Refer directly for Colposcopy or a Loop Electrosurgical Excision Procedure (LEEP), regardless of age, as the risk of underlying cervical intraepithelial neoplasia (CIN 2/3) or invasive cancer is high.
Sexually Transmitted Infections (STIs)
Chlamydia trachomatis: Typically asymptomatic but can cause mucopurulent cervicitis, urethritis, and Pelvic Inflammatory Disease (PID). Diagnosis is via Nucleic Acid Amplification Test (NAAT) of a vaginal swab or first-catch urine.
Treatment: Doxycycline 100 mg orally twice daily for 7 days is first-line in non-pregnant individuals. Azithromycin 1 g orally in a single dose is an alternative, used primarily during pregnancy.
Neisseria gonorrhoeae: Presents with purulent vaginal discharge, dysuria, and pelvic pain. Untreated infections can lead to PID or disseminated gonococcal infection. Diagnosis is via NAAT.
Treatment: Ceftriaxone 500 mg intramuscularly (IM) as a single dose (1 g IM for patients weighing >=150 kg). If chlamydial infection has not been excluded, add Doxycycline 100 mg twice daily for 7 days.
Syphilis ( Treponema pallidum ):
Primary: Painless chancre with indurated borders at the site of inoculation, resolving spontaneously in 3–6 weeks.
Secondary: Generalized maculopapular rash involving the palms and soles, condyloma lata (moist, highly infectious plaques in intertriginous areas), fever, and lymphadenopathy.
Tertiary: Gummas, cardiovascular syphilis, and neurosyphilis (Argyll Robertson pupil).
Diagnostics: Screening is performed with nontreponemal tests (RPR or VDRL); positive results must be confirmed with treponemal-specific tests (FTA-ABS or TP-PA). Nontreponemal titers are used to monitor response to therapy.
Treatment: Penicillin G benzathine 2.4 million units IM in a single dose for primary, secondary, or early latent syphilis. Late latent or syphilis of unknown duration requires 3 doses of 2.4 million units IM administered weekly.
Genital Herpes (HSV): Presents with painful, grouped fluid-filled vesicles on an erythematous base that rupture into shallow, painful ulcers. A prodrome of tingling or burning is common.
Treatment: Antiviral therapy (e.g., Acyclovir, Valacyclovir) reduces the duration and severity of outbreaks but does not cure the latent infection.
Worked Clinical Scenario
A 24-year-old female presents for a routine wellness exam and cervical cancer screening. Her last Pap smear was performed at age 21 and was normal. The cytology report returns showing atypical squamous cells of undetermined significance (ASC-US). The patient is anxious and asks if she needs a colposcopy. Following the ASCCP guidelines, the clinician counsels the patient that because she is under the age of 25, the preferred management is to repeat cytology alone in 12 months, rather than performing reflex HPV testing or immediate colposcopy. This conservative approach is recommended because HPV clearance rates are high in this age group, and transient abnormalities are likely to regress spontaneously without clinical intervention.
Clinical Traps & Pearls
Trap 1: Metronidazole Alcohol Interaction. Patients receiving metronidazole for BV or trichomoniasis must be emphatically instructed to avoid all alcohol consumption (including mouthwashes and cough syrups containing alcohol) during treatment and for at least 72 hours after completion of the course. Failure to do so can trigger a severe disulfiram-like reaction characterized by flushing, throbbing headache, vomiting, chest pain, and hypotension.
Trap 2: Mismanaging Abnormal Pap Smears in Women Under 25. Clinicians often mistakenly apply the same guidelines for abnormal Pap smears to all adult women. For women aged 21-24 with ASC-US or LSIL, immediate colposcopy is not recommended. Instead, repeat cytology in 12 months is the standard of care due to the high rate of spontaneous resolution in young women and the risk of cervical incompetence from unnecessary excision procedures (like LEEP).
Trap 3: Outdated Chlamydia Treatment. A common exam trap is selecting azithromycin 1 g orally as the first-line treatment for chlamydia. In 2021, the CDC updated its guidelines to recommend Doxycycline 100 mg twice daily for 7 days as the first-line treatment for chlamydia in non-pregnant adults, due to higher efficacy in rectal chlamydia. Azithromycin is now a second-line/alternative therapy, except in pregnant patients where doxycycline is contraindicated.